Check patentability & draft patents in minutes with Patsnap Eureka AI!

Preparation and application of bionic nanoparticles based on double-drug co-assembly and having phototherapy and chemotherapy functions

A biomimetic nano, co-assembly technology, applied in the field of biomedicine, achieves the effects of good stability, simple preparation process, and enhanced specific recognition.

Active Publication Date: 2022-06-03
FUZHOU UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the co-construction of nano-drug delivery system based on SF and PPL for the synergistic treatment of liver cancer has not been reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation and application of bionic nanoparticles based on double-drug co-assembly and having phototherapy and chemotherapy functions
  • Preparation and application of bionic nanoparticles based on double-drug co-assembly and having phototherapy and chemotherapy functions
  • Preparation and application of bionic nanoparticles based on double-drug co-assembly and having phototherapy and chemotherapy functions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

This embodiment provides a method for preparing propranolol-sorafenib-indocyanine green co-assembled nanoparticles (PSINPs), the method comprising the following steps:

Accurately weigh 0.00400 g of propranolol (PPL) and dissolve it in 1 mL of ethanol to obtain 4 mg / mL solution A; accurately weigh 0.00400 g of sorafenib (SF) and dissolve it in 1 mL of ethanol , to obtain 4 mg / mL solution B; accurately weigh 0.00400 g of indocyanine green (ICG) and dissolve it in 1 mL of ultrapure water to obtain 4 mg / mL solution C; take 50 μL of solution A and 50 μL of Solution B was mixed to obtain mixed solution AB; 50 μL of solution C was dispersed in 850 μL of ultrapure water to obtain diluted solution C; 100 μL of mixed solution AB was added dropwise to 900 μL of the diluted solution in a vortex state In C, the aqueous solution of the nanoparticle PSINPs is obtained.

[0035] like figure 2 As shown, the average particle size of the PSINPs prepared in this example is about 150 nm.

Embodiment 2

This embodiment provides the preparation method of HepG2 cell lysate and HepG2 cell membrane precipitation, and the method is as follows:

Preparation of HepG2 cell lysate: HepG2 cells were cultured to a growth density of 80-90%, digested with 0.25 wt% trypsin containing EDTA for 3-5 min, and centrifuged at 1500 rpm for 5 min to obtain cell pellets. The cells were washed 3 times with normal saline, dispersed in 0.25× normal saline containing 1 mM phenylmethylsulfonyl fluoride (PMSF), and placed in a refrigerator at 4°C for 1 to 2 hours to obtain HepG2 cell lysate.

[0037] Preparation of HepG2 cell membrane pellets: HepG2 cells were cultured to a growth density of 80-90%, digested with 0.25 wt% trypsin containing EDTA for 3-5 min, and centrifuged at 1500 rpm for 5 min to obtain cell pellets. The cells were washed 3 times with normal saline, dispersed in 0.25× normal saline containing 1 mM PMSF, and placed in a refrigerator at 4°C for 1 to 2 hours; then the cell suspension was t...

Embodiment 3

This embodiment provides a preparation method of HepG2 cell membrane-encapsulated PSINPs (CM@PSINPs), and the method includes the following steps:

The HepG2 cell membrane dispersion liquid collected in Example 2 was mixed with the aqueous solution of PSINPs nanoparticles prepared in Example 1 at a volume ratio of 1:10, and then ultrasonicated (250 W, 40 KHz) for 10 min at room temperature. That is, the aqueous solution of the nanoparticle CM@PSINPs is obtained.

[0039] like image 3 As shown, the average particle size of the CM@PSINPs prepared in this example is about 160 nm.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of biological medicine, and particularly relates to preparation and application of bionic nanoparticles based on double-drug co-assembly and having phototherapy and chemotherapy functions. The bionic nanoparticle is composed of a shell and a nano core coated by the shell, the shell is a HepG2 cell membrane, and the nano core is formed by assembling an anti-tumor hydrophobic drug sorafenib, an anti-cardiovascular disease hydrophobic drug propranolol and a photosensitizer indocyanine green. The biomimetic nanoparticles can be specifically accumulated at a liver cancer part through a cell membrane homologous recognition effect, and can accurately and efficiently release drugs under the irradiation of 808 nm laser, so that a multi-drug-multi-therapy combined anti-liver cancer effect is realized, and the biomimetic nanoparticles have a remarkable inhibition effect on the growth of liver cancer and have a wide application prospect in preparation of anti-liver cancer drugs.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the preparation and application of a biomimetic nanoparticle with photo-chemotherapy based on dual-drug co-assembly. Background technique [0002] Liver cancer is the most common primary liver cancer and can be caused by chronic hepatitis B virus, hepatitis C virus infection, diabetes and other diseases. Due to its insidious onset, difficult early diagnosis, and high degree of malignancy, most patients have reached the middle and late stages when diagnosed. Combined with the development of multidrug resistance during treatment, metastasis to adjacent or distant tissues, and severe side effects, the mortality rate of liver cancer remains high. Currently, the main treatments for liver cancer include surgical resection, liver transplantation, chemotherapy or radiotherapy. Among them, surgical resection is the first choice for the treatment of early stage liver canc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/51A61K47/46A61K41/00A61K31/44A61K31/138A61P35/00B82Y5/00B82Y40/00
CPCA61K9/5176A61K9/5192A61K41/0057A61K31/44A61K31/138A61P35/00B82Y5/00B82Y40/00A61K2300/00
Inventor 邵敬伟罗邦悦李林燕
Owner FUZHOU UNIV
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com